论文部分内容阅读
目的 检测婴幼儿血管瘤组织中抑癌基因 p1 6及肿瘤坏死因子相关凋亡诱导配体(TRAIL)的表达 ,并探讨它们在血管瘤增生、消退过程中的作用。方法 采用免疫组化SP法检测 32例增生期、2 0例消退期血管瘤及 1 4例血管畸形组织中p1 6和TRAIL的表达。结果 p1 6在增生期和消退期血管瘤组织中阳性表达率分别为 78.1 % (2 5/ 32 )、90 .0 % (1 8/ 2 0 ) ,血管畸形组织中全部为阴性。经秩和检验 :Hc=2 6 .6 ,三者之间差异存在显著性意义 (P <0 .0 1 ) ,两者之间差异有显著性意义(P <0 .0 5)。TRAIL在增生期和消退期血管瘤组织中阳性表达率分别为 2 1 .9% (7/ 32 )、80 .0 % (1 6/2 0 ) ,血管畸形中全部为阴性 ,卡方检验 :χ2 =2 7.8,三者之间差异存在显著性意义 (P <0 .0 1 ) ,两两之间比较经 χ2 分割 ,增生期与消退期之间有差异 (P <0 .0 5) ,消退期与血管畸形之间有差异 (P <0 .0 5) ,增生期与血管畸形之间无差异 (P >0 .0 5) ,血管瘤与血管畸形之间有差异。结论 p1 6和TRAIL的表达水平与血管瘤的增生、消退有关 ,p1 6可抑制内皮细胞的分裂增殖 ,TRAIL可通过诱导内皮细胞凋亡发挥作用 ,两者均可促进血管瘤消退
Objective To detect the expression of tumor suppressor gene p1 6 and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in infantile hemangiomas and to explore their role in the proliferation and regression of hemangiomas. Methods Immunohistochemical SP method was used to detect the expression of p16 and TRAIL in 32 cases of proliferative phase, 20 cases of regression hemangiomas and 14 cases of vascular malformations. Results The positive rates of p16 expression in hemangiomas were 78.1% (25/32) and 90.0% (18/20%) respectively, all of them were negative in vascular malformations. The rank sum test: Hc = 26.6, the difference between the three significant (P <0.01), the difference between the two was significant (P <0.05). The positive rate of TRAIL expression in proliferating and retiring hemangiomas was 21.9% (7/32) and 80.0% (16/200), respectively, and all the vascular malformations were negative. Chi-square test: χ2 = 2 7.8, there was a significant difference between the three (P <0.01). There was a significant difference between the two groups (χ2 = 2.57, P <0.05) There was a significant difference between regression and vascular malformations (P <0.05). There was no difference between vascular hyperplasia and vascular malformations (P> 0.05). There was a difference between hemangiomas and vascular malformations. Conclusion The expressions of p16 and TRAIL are related to the proliferation and regression of hemangiomas. P1 6 can inhibit the proliferation and proliferation of endothelial cells. TRAIL can induce the apoptosis of endothelial cells, both of which can promote the regression of hemangiomas